Search for CDMO companies in India and you get long lists of names, sometimes more than a hundred. Names are the easy part. The hard part is working out which of several hundred contract manufacturers has the right plant, the right approval and the right capacity for your product. This guide explains how the Indian CDMO landscape is organised, where the main clusters are, and the checks that separate a good partner from an expensive mistake.
Why buyers look at India for contract manufacturing
India is one of the world's largest producers of generic medicines and APIs. It also has more US FDA–inspected manufacturing sites than any country other than the United States. Over two decades, its manufacturers have built deep experience in regulated-market filings, and many sites hold EU-GMP, US FDA, WHO-GMP, PIC/S-aligned and other national approvals.
Two things make it attractive, and they only work together:
- Cost structure. Labour, utilities, construction and validation cost materially less than equivalent capacity in the US or Europe. Minimum order quantities are usually lower too, which makes single-market launches and smaller portfolios viable.
- Approved plants. A site that has passed EU or US inspection has shown that its quality systems, documentation and data integrity stand up to the strictest scrutiny. That credibility helps registrations in other markets as well.
Cost without approvals is a false economy. Approvals without a cost advantage remove the reason to look further afield.
The main types of CDMO in India
Indian CDMOs range from small speciality labs to large groups running a dozen or more plants. Grouping them by what they do is far more useful than ranking them by size.
| Type of CDMO | What they typically offer | Good fit for |
|---|---|---|
| Integrated, full-service groups | Discovery chemistry, process development, API and finished dose, often at several approved sites | Innovators and larger generic companies that want one partner across stages |
| Formulation development and manufacturing specialists | Oral solids, liquids, topicals, softgels; development, stability, tech transfer and commercial supply | Generic and private-label projects, line extensions, new markets |
| API and intermediate specialists | Custom synthesis, generic APIs with DMFs or CEPs, intermediates and key starting materials | Formulators who need a qualified API source or a second source |
| Sterile and injectable specialists | Vials, ampoules, pre-filled syringes, lyophilisation, ophthalmics | Hospital and tender products; projects where capacity is scarce |
| Biologics and vaccine CDMOs | Cell line and process development, mammalian and microbial manufacture, fill-finish | Biosimilar developers and biotech companies |
| Niche and emerging specialists | Peptides, high-potency APIs, ADC payloads, hormones, complex generics | Specialist molecules where containment or chemistry is the constraint |
Most mid-sized manufacturers specialise narrowly. A company that excels at ophthalmics may not make oral solids at all. Start from your dosage form and work outwards.
Where the clusters are
Manufacturing is concentrated in a handful of regions, each with its own strengths and supply chain.
| Region | Known for |
|---|---|
| Hyderabad and Telangana | APIs and intermediates, oral solids, injectables; a large share of India's bulk drug output |
| Visakhapatnam (Andhra Pradesh) | Dedicated pharma city with API and formulation plants, close to a major port |
| Ahmedabad, Vadodara and Ankleshwar (Gujarat) | Formulations, APIs and chemical intermediates; strong regulated-market presence |
| Mumbai, Pune and Goa | Formulations, sterile products and development centres |
| Bengaluru (Karnataka) | Biologics, research services and specialty APIs |
| Baddi (Himachal Pradesh) and Sikkim | High-volume oral solids and liquids, much of it for domestic and semi-regulated markets |
| Chennai and Indore–Pithampur | Formulations, softgels and export-oriented units |
Location matters less than the plant's approvals, but it does affect logistics, cold chain options and how easily you can visit for an audit.
Third-party manufacturing or a full CDMO?
Buyers often use "third-party manufacturing", "contract manufacturing" and "CDMO" as if they mean the same thing. They don't, and picking the wrong arrangement costs time and money.
- Third-party manufacturing means an existing product, with its formulation and often its dossier, is made and packed under your brand. It is fast and relatively cheap.
- A CDMO adds development: formulation work, analytical methods, stability, bioequivalence where needed, and dossier preparation.
The practical test: if a suitable product already exists and you only need it made, third-party manufacturing is enough. If you need something developed, or a dossier you can file in your own name, you need a CDMO.
Approvals belong to plants, not companies
This is the point buyers most often get wrong. Approvals attach to a specific site and dosage form, never to a company as a whole. A large manufacturer may hold US FDA approval at one plant, EU-GMP at another and only WHO-GMP at a third. "We are a US FDA–approved company" tells you nothing about the site that will make your product.
Before you go further, establish:
- the exact site that will manufacture your product, with its address;
- which approvals that site holds, for which dosage forms, and when it was last inspected;
- whether those certificates can be verified in public databases (EudraGMDP for EU-GMP, the FDA inspection database, or the national regulator);
- any recent warning letters, import alerts or Form 483 observations, and how they were closed.
How to choose: a short checklist
- Define your brief first. Product, strength, pack, target market, regulatory route and a 12–36 month volume forecast. Manufacturers quote faster and more sharply against a clear brief.
- Match the dosage form. Ask for comparable products and batch sizes the site already runs.
- Confirm capacity. Ask when a slot actually opens. For sterile products, capacity is usually the binding constraint.
- Settle dossier ownership. Will you own it, can it be filed in your name, is it exclusive, and what happens on termination? This causes more disputes than any other term.
- Check the data package. CoA format, stability protocol and the documents your regulator will ask for.
- Audit. A physical or virtual audit before the first commercial order is normal practice. Reluctance to allow one is a red flag.
Trends worth knowing in 2026
- Diversification away from single-country supply is bringing new development and API work to Indian sites, especially for regulated markets.
- Specialist capacity is growing in peptides, high-potency APIs, ADC payloads and complex injectables.
- Quality expectations keep rising. Nitrosamine risk assessments, data integrity and India's updated GMP rules are now part of any serious qualification.
- US tariffs on patented medicines do not currently apply to generics, which make up most of India's export volume. See our guide to the US pharma tariffs.
How we can help
We work with GMP-certified contract manufacturers in India and in other producing regions, and we verify site certificates at onboarding. Describe your project once — product, dosage form, volume, target market and regulatory need — and we come back with manufacturers whose approvals and capacity actually match. Start with our contract manufacturing services, read our guide to choosing a CDMO, or send a request for a quote. If you need an API rather than a finished product, use our API enquiry form.
Frequently Asked Questions(FAQs)
How many CDMO companies are there in India?
Several hundred, ranging from small speciality formulation developers to large groups running many approved plants. The number matters less than finding a site with the right dosage form, approvals and capacity for your product.
What is the difference between a CDMO and third-party manufacturing in India?
Third-party manufacturing makes an existing product under your brand. A CDMO also provides development: formulation, analytical methods, stability, bioequivalence where needed and dossier preparation. If you need a product developed or a dossier in your own name, you need a CDMO.
How do I verify an Indian CDMO's GMP certification?
Ask for the certificate for the specific site that will make your product, then check it against the issuing authority's records, such as EudraGMDP for EU-GMP or the FDA inspection database. Confirm it covers your dosage form and is current. Approvals are site-specific, never company-wide.
What minimum order quantities do Indian CDMOs accept?
It depends on the dosage form and whether the order is stock supply or a dedicated batch. Indian CDMOs generally accept lower minimums than the largest global platforms. A credible 12–36 month volume forecast usually secures better terms than one large order.
How long does it take to start manufacturing with an Indian CDMO?
For an existing product under a third-party arrangement, a few months. Where formulation development, bioequivalence and a new dossier are needed, expect 18 months to three years. Sterile injectables generally take longer than oral solids.
Can Indian CDMOs supply dossiers for my market?
Many hold ready dossiers in CTD, EU-CTD or ACTD format, often with bioequivalence data. Agree before contracting whether the dossier can be filed in your name, whether it is exclusive and what happens to it on termination.
